SBIR Phase I: Preventing Biofilms on Indwelling Medical Devices with Novel Anti-Biofilm Small Molecules

SBIR 第一阶段：利用新型抗生物膜小分子预防留置医疗器械上的生物膜

• 批准号: 1046012
• 负责人: Eva Garland
• 金额: $ 15万
• 依托单位: Agile Sciences Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1046012&HistoricalAwards=false
• 关键词: SBIR; Phase; Preventing; Biofilms; Indwelling

This Small Business Innovation Research (SBIR) Phase I project describes a new approach for reducing infections associated with indwelling medical devices. Bacteria on medical devices are particularly challenging to treat because they form a protective matrix called a biofilm on the surface of the device. It is very difficult to access bacteria in the biofilm state, and systemic use of antibiotics is generally ineffective against bacteria in biofilms. We have discovered a class of novel small molecules that inhibits bacteria's ability to form biofilms as well as disperses pre-formed bacterial biofilms. This is the only class of small molecules reported that is able to disperse pre-formed biofilms from both gram-positive and gram-negative bacteria. Both gram-positive and gram-negative bacterial biofilms have been identified on medical devices. For this Phase I SBIR, we propose to test the feasibility of incorporating our anti-biofilm compound into medical devices through a covalent bonding technique. The broader impact/commercial potential of this project addresses both health and economic burdens associated with infections of medical devices. Indwelling medical devices are associated with approximately 1 million infections and 50,000 deaths in the US each year, and hundreds of millions of dollars are spent annually treating these infections. Furthermore, infections associated with indwelling medical devices currently account for approximately one half of all hospital-acquired infections. It is estimated that the direct cost of eliminating infections known to be related to device biofilms is approximately $650 million each year.

小型企业创新研究（SBIR）第一阶段项目描述了一种减少与留置医疗器械相关的感染的新方法。 医疗器械上的细菌特别具有挑战性，因为它们在器械表面形成一种称为生物膜的保护性基质。 很难接近生物膜状态的细菌，全身使用抗生素通常对生物膜中的细菌无效。 我们已经发现了一类新型的小分子，其抑制细菌形成生物膜的能力以及分散预先形成的细菌生物膜。 这是报道的唯一一类能够分散来自革兰氏阳性和革兰氏阴性细菌的预形成生物膜的小分子。革兰氏阳性菌和革兰氏阴性菌生物膜均已在医疗器械上鉴定。 对于第一阶段SBIR，我们建议测试通过共价键合技术将我们的抗生物膜化合物掺入医疗器械的可行性。 本项目的更广泛影响/商业潜力解决了与医疗器械感染相关的健康和经济负担。 在美国，留置医疗设备每年与大约100万例感染和50，000例死亡相关，并且每年花费数亿美元治疗这些感染。 此外，与留置医疗器械相关的感染目前约占所有医院获得性感染的一半。 据估计，消除已知与器械生物膜相关的感染的直接成本每年约为6.5亿美元。